Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer—A population study
Women's Health · 2023
DOI: 10.1177/17455057231164551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Women's Health, 2023. Verfasst von Christine Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine, University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antineoplastic Agents, Radiotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Factors that impact recurrence in stages IB to IV include larger tumor, high-risk histology, older age, and lymphovascular invasion (LVI); however, local studies on risk factors for recurrence in British Columbia and our local recurrence patterns have not been well studied. Furthermore, the efficacy of treatment modalities including surgery and chemoradiation in the different stages of cervical cancer have not been clarified in this population.
Objectives
The purpose of this study is to determine the disease and treatment characteristics of stages IB to IV cervical cancer which are associated with survival differences within British Columbia. Methods/Design: We performed a retrospective population study. A chart review on cervical cancer patients in British Columbia between 1 January 2010 and 31 December 2017 was done. Demographic data and treatment details were collected. Data were analyzed using multivariate Cox regressions, pairwise comparison using the Log-Rank test, and chi-square tests.
Results
We included 780 patients (stage I: 31.5%, II: 20.0%, III: 34.5%, and IV: 3.3%). LVI and p16 negativity were associated with decreased overall survival (OS), and multivariate analyses show them to be independent risk factors for poorer survival. Surgical resection in stage I was associated with improved survival, but not with stages II–IV. The use of radical radiation therapy (RT), brachytherapy, and concurrent chemotherapy were independently associated with improved survival in stages II–IV. Peri-RT chemotherapy was not associated with survival benefit in adeno/adenosquamous carcinoma. There were 180 recurrences (23.1%), mostly distant metastases (42.8%). There were fewer recurrences after resection of tumors
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
- Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
- Department of Radiation Oncology, BC Cancer-Abbotsford, Abbotsford, BC, Canada.
- Department of Mathematics and Statistics, University of the Fraser Valley, Abbotsford, BC, Canada.
- Department of Medical Oncology, BC Cancer-Abbotsford, Abbotsford, BC, Canada.
- Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Christine Wang
Zitieren
APA
Wang, C., Lester, B., Huang, L., Sun, S., & Ko, J. J. (2023). Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer—A population study. Women's Health. https://doi.org/10.1177/17455057231164551
Vancouver
Wang C, Lester B, Huang L, Sun S, Ko JJ. Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer—A population study. Women's Health. 2023. doi:10.1177/17455057231164551
BibTeX
@article{Wang2023,
author = {Wang, Christine and Lester, Beverly and Huang, Longlong and Sun, Shaun and Ko, Jenny J},
title = {Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer—A population study},
journal = {Women's Health},
year = {2023},
doi = {10.1177/17455057231164551}
}
EUVIMED